

News Releases

All Years

Search

Go

[Advanced Search](#)

AUG 7, 2023

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

MAY 30, 2023

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 8, 2023

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

MAR 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

JAN 4, 2023

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

NOV 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

NOV 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

NOV 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Show per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=10&o=30>